Botulinum toxin for the treatment of cervical dystonia

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 12, 2001, Pages 1985-1994

  Tintner, R ^a   Jankovic, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Botox ; Botulinum toxin; Cervical dystonia; Dystonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOQUINOLINE DERIVATIVE; AUTOANTIBODY; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHLOROQUINE; HYDROXYCHLOROQUINE; LEVODOPA; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TRIHEXYPHENIDYL;

ANTIBODY PRODUCTION; BASAL GANGLION; BODY POSTURE; BRAIN CORTEX; CLINICAL FEATURE; CONTROLLED STUDY; DENERVATION; DILUTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SYNTHESIS; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; HEAD MOVEMENT; HUMAN; IMMUNITY; INJECTION SITE; INVOLUNTARY MOVEMENT; MOTOR DYSFUNCTION; MUSCLE SPASM; MUSCLE SPINDLE; MYOPATHY; NECK MUSCLE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PAIN; PHARYNX DISEASE; RAT; REVIEW; RISK ASSESSMENT; SEROTYPE; SIDE EFFECT; SYMPTOM; THALAMUS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CLINICAL TRIALS; DRUG RESISTANCE; HUMANS; SYNAPSES; TORTICOLLIS;

EID: 0035195090     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.12.1985     Document Type: Review

References (83)

1. Dystonic disorders
2. Clinical-genetic spectrum of primary dystonia
3. Comparison of acute- and delayed-onset posttraumatic cervical dystonia
4. Can peripheral trauma induce dystonia and other movement disorders? Yes!
5. Clinical comparison of tardive and idiopathic cervical dystonia
6. The pathophysiology of primary dystonia
7. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia
8. Role of the vestibular system in the pathophysiology of spasmodic torticollis
9. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy
10. Change in pattern of muscle activity following botulinum toxin injections for torticollis
11. Long-term botulinum toxin treatment of cervical dystonia-EMG changes in injected and noninjected muscles
12. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale
13. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin
14. Treatment of cervical dystonia: A comparison of measures for outcome assessment
15. Head tremor in cervical dystonia
16. Quantification of sensory trick impact on tremor amplitude and frequency in 60 patients with head tremor
17. Arm tremor in cervical dystonia differs from essential tremor and can be classified by onset age and spread of symptoms
18. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation
19. Pharmacological and surgical options for the treatment of cervical dystonia
20. Outcome of selective ramisectomy for botulinum toxin resistant torticollis
21. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia
22. Symptomatic and functional outcome of surgical treatment of cervical dystonia
23. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis
24. How botulinum and tetanus neurotoxins block neurotransmitter release
25. Pharmacology of botulinum toxin
26. Neurotoxins affecting neuroexocytosis
27. Pharmacology and immunology of botulinum toxin serotypes
28. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans
29. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
30. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site
31. Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial
32. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms
33. How does botulinum toxin work?
34. Cervical echomyography in cervical dystonia and its application to the monitoring for muscle afferent block (MAB)
35. Quantifying the spread of botulinum toxin through muscle fascia
36. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections
37. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function
38. Distant effects of locally injected botulinum toxin: A double-blind study of single fiber EMG changes
39. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases
40. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis
41. Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model
42. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis
43. Double-blind study of botulinum toxin in spasmodic torticollis
44. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp
45. The median paralysis unit: A more pharmacologically relevant unit of biologic activity for botulinum toxin
46. In vitro biological activity and toxicity of tetanus and botulinum neurotoxins
47. Comparison of in vivo and in vitro mouse bioassays for botulinum toxin antagonists
48. Some unresolved issues with botulinum toxin
49. Dose standardization of botulinum toxin
50. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia
51. Dysbot: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - Assuming a ratio of 4:1
52. Human response to botulinum toxin injection: Type B compared with type A
53. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study
54. A correlation between differential structural features and the degree of endopeptidase activity of type A botulinum neurotoxin in aqueous solution
55. Use of botulinum toxin type A in the treatment of cervical dystonia
56. Evidence-based medicine in botulinum toxin therapy for cervical dystonia
57. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis
58. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: A retrospective chart review
59. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency
60. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three clinical trials
61. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
62. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
63. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
64. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
65. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor
66. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport
67. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial
68. Experience with botulinum toxin in cervical dystonia
69. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia
70. Quantitative EMG in cervical dystonia
71. Electromyography in cervical dystonia: Changes after botulinum and trihexyphenidyl
72. Utility of an EMG mapping study in treating cervical dystonia
73. Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance
74. EMG-guided injections of botulinum toxin: An opposing viewpoint
75. Botulinum toxin treatment of spasmodic torticollis
76. Dysphagia after botulinum toxin injections for spasmodic torticollis: Clinical and radiologic findings
77. Botulinum a toxin for spasmodic torticollis: Multiple vs. single injection points per muscle
78. Botulinum toxin therapy, immunologic resistance, and problems with available materials
79. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: A blinded evaluation
80. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: Correlation with clinical response
81. A radioimmuno-precipitation assay for antibodies to botulinum A
82. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies
83. Botulinum toxin: Clinical implications of antigenicity and immunoresistance